Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARYEL NICOLEAU

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1093880957
CMS profile
4741
Location
QUEENS VILLAGE, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$5,132.18

252 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,894.31 248
Education $237.87 4

By paying entity

PY2021 · entire year · sorted by reported total

Page 6 of 6; records 251–252 of 252 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARYEL NICOLEAU

NPI 1093880957 · CMS profile ID 4741

Allopathic & Osteopathic Physicians / Internal Medicine

QUEENS VILLAGE, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–252 of 252 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093880957?year=2021&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARYEL NICOLEAU, NPI 1093880957, CMS profile ID 4741. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–252 of 252 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093880957?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ARYEL NICOLEAU, NPI 1093880957, CMS profile ID 4741. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–252 of 252 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093880957?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ARYEL NICOLEAU, NPI 1093880957, CMS profile ID 4741, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–252 of 252 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1093880957?year=2021&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

252 matching records · $5,132.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 252 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–252 of 252.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $10.0601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797179745 CMS
Merck Sharp & Dohme Corporation $17.6601/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848676525 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,063.35 203
PY2020 $3,269.44 186
PY2021 $5,132.18 252
PY2022 $4,034.63 187
PY2023 $5,146.30 247
PY2024 $5,256.78 229
PY2025 $4,772.53 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $141,019.00 35
PY2024 Principal investigator $31,400.94 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 12/24/2025 Non-covered Recipient Entity
A One Clinical Network Llc
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226080183
Principal investigator 1 F. Hoffmann-La Roche AG $2,691.00 12/19/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211566116
Principal investigator 1 SANOFI US SERVICES INC. $29,300.00 12/12/2025 Non-covered Recipient Entity
A One Clinical Network Llc
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226080179
Principal investigator 1 SANOFI US SERVICES INC. $2,253.00 12/12/2025 Non-covered Recipient Entity
Tropical Clinical Trials
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226096651
Principal investigator 1 SANOFI US SERVICES INC. $104.00 12/12/2025 Non-covered Recipient Entity
Tropical Clinical Trials
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226096660
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,595.00 12/10/2025 Non-covered Recipient Entity
MAINSTREET HEALTH
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185552901
Principal investigator 1 Genentech, Inc. $2,585.00 10/29/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211566153
Principal investigator 1 Genentech, Inc. $7,582.00 10/29/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211566156
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044824
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044826
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044838
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044840
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044842
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044844
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044846
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044848
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044850
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044852
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044854
Principal investigator 1 Genentech, Inc. $23,000.00 04/23/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211566127
Principal investigator 1 Genentech, Inc. $2,838.00 04/22/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211566132
Principal investigator 1 Genentech, Inc. $4,400.00 04/22/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211566145
Principal investigator 1 Genentech, Inc. $1,830.00 04/22/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211566149
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 03/14/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044822
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 02/12/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044820
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 02/12/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044836
Principal investigator 1 Genentech, Inc. $2,838.00 01/29/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211566119
Principal investigator 1 Genentech, Inc. $4,400.00 01/29/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211566123
Principal investigator 1 Genentech, Inc. $1,830.00 01/29/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211566136
Principal investigator 1 Genentech, Inc. $23,000.00 01/29/2025 Non-covered Recipient Entity
A1 CLINICAL NETWORK LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211566140
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 01/22/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044818
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 01/22/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044828
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 01/22/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044830
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 01/22/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044832
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 01/22/2025 Non-covered Recipient Entity
A1 Clinical Network LLC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244044834